That’s not because of the FDA, that’s because of CEPS. If the USG negotiated drug prices the way France does, there’d be far less disparity in average pricing. (Given the continual litany of safety, efficacy, and dosage control issues with imported drugs, FDA isn’t regulating them enough, largely because the inspection budget just isn’t there.)